Research Programme: PTP 1B inhibitors - DepYmed
Alternative Names: PTP-1B inhibitors - DepYmedLatest Information Update: 18 Nov 2022
At a glance
- Originator DepYmed
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein-tyrosine-phosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Rett syndrome; Solid tumours
Most Recent Events
- 10 Mar 2022 DepYmed plans a phase I trial for PTP1B inhibitors for Rett syndrome in second half of 2023
- 10 Mar 2022 DepYmed and Monash University enters into a sponsored research agreement to explore PTP 1B inhibitors in treatment of Solid tumours
- 10 Mar 2022 Preclinical trials in Solid tumours in USA (PO)